CMP Therapeutics appoints ceo

Receives loan to support clinical trial of lead product for common cold

London-based CMP Therapeutics (CMPT) has appointed Neill Moray Mackenzie as chief executive.

Mackenzie joins the developer of therapeutics for colds, flu and allergy with a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore). He was most recently SVP for business development and corporate strategy at Medigene and ceo of Roji (London). In addition, MacKenzie was formerly a departmental head in vaccine r&d at Wellcome and a Wellcome lecturer in immunology at the University of London.

CMPT has received €1.5m convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported funding from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.

You may also like

Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery

Palvella's QTORIN achieves positive Phase III results

Working in collaboration with MedPharm, the biopharma company announced positive topline results from its Phase 3 SELVA study of QTORIN rapamycin, paving the way for the company to prepare for commercial-scale manufacturing
Drug Delivery

New cancer drug delivery system boosts absorption of Paclitaxel

Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb
Research & Development

3PBIOVIAN and Colombia's National Cancer Institute partner to develop first locally produced oncology biosimilar

The CDMO has signed an agreement with Colombia's Instituto Nacional de Cancerología to develop a biosimilar monoclonal antibody for an oncology indication, with technology transfer planned to enable domestic manufacturing
Subscribe now